PRESS RELEASE

Launch of UK's First AI for Longevity Hub at King's College London and its Bold Plans for 2020 and Beyond

November 13, 2019, London, UK: The Longevity AI Consortium has officially launched at King's College London at the inaugural AI for Longevity Summit.

The Consortium, recently established as a major initiative of Ageing Research at King's (ARK), will focus initially on core longevity academic-industry R&D, including the development of biomarkers of ageing, health and longevity (including experimental biomarkers of longevity) and novel implementation of life and health data analytics. In 2020, after achieving several key scientific and funding milestones, AI-enabled solutions for physical, mental and financial wellness will become a major focus, and an AI Longevity Accelerator will be launched to serve as a much-needed bridge between start-ups and major UK investors, creating for the first time a dedicated infrastructure for increased investments and developments in this important sector.

"AI holds enormous potential to rapidly accelerate the implementation of Longevity R&D. The nation is home to multiple centres of AI for Healthcare, but not a single Longevity AI Consortium. We are changing this through our unique academic-industry focus on preventive and personalised physical, mental and financial health, marking us out from other AI and Ageing centres around the

world" said Richard Siow, Ph.D., Director of the [Longevity AI Consortium](#) at King's College London and [Ageing Research at King](#) (ARK).

This landmark one-day event brought together leaders in academia, industry, government officials, clinicians, financial and insurance industry executives for the first time to discuss the importance of policy and AI technologies for Longevity, gathering an unprecedented number of academic, clinical and industry experts at the intersection of AI for health and finance to highlight recent developments in utilising AI in technologies for Longevity R&D that are enabling a paradigm shift from treatment to prevention and from traditional healthcare to AI-empowered precision health and therapeutics.

"Longevity is becoming mainstream among scientists, entrepreneurs, investors, major financial, tech and healthcare corporations, and progressive governments. AI holds unprecedented power to translate research into tangible solutions to extend healthy longevity, and it is with this mission in mind that Deep Knowledge Group and its associated subsidiaries are supporting the Longevity AI Consortium at King's College London, the UK's first AI for Longevity Hub." said Dmitry Kaminskiy, Managing Partner of Deep Knowledge Ventures and its Longevity-focused hybrid investment fund [Longevity.Capital](#), Co-Founder of [Aging Analytics Agency](#), and Managing Trustee of the [Biogerontology Research Foundation](#).

The [AI for Longevity Summit](#) is organized with strategic support of [Aging Research at King's](#) (ARK), the [Biogerontology Research Foundation](#), [Deep Knowledge Group,](#) [Aging Analytics Agency](#) and [Collider Health](#) and Longevity International. The [International Longevity Policy and Governance Summit](#) is running alongside on the same day.

About the Summits
This landmark one-day event brings together leaders in the longevity industry, government officials, scientists, financial and insurance industry executives under the same roof for the first time. The International Longevity Policy and Governance Summit focuses on the efforts of longevity-progressive governments to transform the challenge of ageing population into the opportunity of healthy longevity, with key lessons learned from Japan, Israel, Switzerland, USA and UK. The AI for Longevity Summit brings together expertise from the AI, longevity and finance sectors to shift treatment to prevention and from traditional healthcare to AI-empowered precision health.

About the Longevity AI Consortium
The Longevity AI Consortium established by Ageing Research at King's (ARK), will serve as a leading academic-industry R&D hub for AI-driven personalised and preventive diagnostics, prognostics and therapeutics. The advances in genetics, artificial intelligence and the growing availability of health data present an opportunity to develop advanced personalised consumer and patient care. The aims of the Longevity AI Consortium include the identification of novel longevity and healthy ageing biomarkers, accelerated diagnosis of age-related health decline, with increased accuracy, refining demographic and clinical methods to facilitate recruitment, retention and ongoing reappraisal, the development of personalised physical, mental and financial health and longevity to better implement and promote effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure and financial planning.